A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral

Who is this study for? Patients with Urologic Diseases
What treatments are being studied? Autologous Engineered Urethral Construct
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males. The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 21
Maximum Age: 75
Healthy Volunteers: f
View:

• Stricture of the urethra meeting the following criteria:

• a) History of at least one 15-60 mm in length, as determined by urethrography. c) Contains at least 1 strictured segment through which a 16 Fr flexible cystoscope cannot be atraumatically passed.

• Patients must be available for all follow-up visits.

• Ability to speak English.

Locations
United States
California
University of California San Francisco
NOT_YET_RECRUITING
San Francisco
North Carolina
Wake Forest Institute for Regenerative Medicine (WFIRM)
RECRUITING
Winston-salem
Contact Information
Primary
Mary-Clare Day, RN, BSN
mday@wakehealth.edu
336-713-1343
Time Frame
Start Date: 2026-03
Estimated Completion Date: 2029-12
Participants
Target number of participants: 10
Treatments
Experimental: Autologous Engineered Urethral Construct
All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
Related Therapeutic Areas
Sponsors
Collaborators: United States Department of Defense
Leads: Wake Forest University Health Sciences

This content was sourced from clinicaltrials.gov